Embattled drugmaker Mylan sought Monday to temper growing outrage over the skyrocketing cost of its lifesaving EpiPen, announcing it would offer a generic version of the auto-injector in the coming weeks that would sell for roughly half the price.
The company said the generic of the EpiPen — which delivers epinephrine to counteract severe allergic reactions to food or bee stings — will be identical to the branded version except for its list price of $300 for a two-pack vs. about $600 for the brand.
Although some analysts applauded the move, other observers were critical, saying the company needed to do much more to cut prices.
“Clearly, if you are a consumer and you have a health plan that has a deductible or co-pay, this [generic offering] will lower your costs,” said Marianne Udow-Phillips, director of the Center for Healthcare Research & Transformation at the University of Michigan. But even at $300, EpiPen remained “very expensive for a drug needed by many people,” she said.
The watchdog group Public Citizen was more critical, saying it was “not enough to offer an overpriced generic version of [Mylan’s] own branded product.”
“Mylan knows its $600/set of EpiPens is unsustainable, but aims to continue ripping off some segment of the marketplace — both consumers who do not trust or know about the generic, and perhaps some insurers and payers constrained from buying a generic.”
Read More
The group said it would deliver petitions from some 600,000 “outraged consumers and allergy sufferers” to Mylan’s executive offices in Cecil today, calling for regulatory reforms and demanding that the company “truly lower the price” of the EpiPen.
Mylan did not respond to an email Monday seeking comment.
The generic drug giant has come under increasing fire in recent weeks from lawmakers and medical and consumer groups accusing the company of price-gouging. The list price for an EpiPen two-pack has risen from about $100 when Mylan acquired the product in 2007 to just over $600, making it unaffordable for many uninsured consumers or people with high-deductible plans.
Mylan CEO Heather Bresch has defended the increase, saying Mylan receives only $274 of the list price, with the other money going to pharmacy benefit managers, insurers, wholesalers and retail pharmacies.
Last week, Mylan moved to soothe the furor by offering a $300 savings card for the drug and other ways to lower out-of-pocket costs.
The company — which is known for its generic drugs but has been expanding into brand-name products — also noted that it had distributed more than 700,000 EpiPens free to some 65,000 schools.
“Our decision to launch a generic alternative to EpiPen is an extraordinary commercial response,” Ms. Bresch said in a statement Monday. “We understand the deep frustration and concerns associated with the cost of EpiPen to the patient.”
Analysts say Mylan has benefited from little competition. One possible rival, Sanofi US, recalled its Auvi-Q epinephrine injector last fall because of dosage accuracy problems, while the launch of Teva Pharmaceutical Industries’ generic copycat was delayed. Teva is hoping to win regulatory approval next year.
Ms. Udow-Phillips said competition would help lower costs for consumers and insurers alike. “Competition is what brings the cost of drugs down,” she said.
She said some Michigan residents buy their EpiPens in Canada, where — in an environment of government price controls — the injectors sell for about $200 a pack.
“Drug companies seem to do OK in those environments,” she said.
Mylan’s move to sell a generic version of its own brand-name product is unusual in its timing. Typically, brand-name drug companies wait until other generics are on the market to launch what’s known as an authorized generic.
“The weirdness of a generic drug company offering a generic version of its own branded but off-patent product is a signal that something is wrong,” Public Citizen said.
Bernstein Research analyst Ronny Gal called Mylan’s plan to sell a lower-priced EpiPen “a smart move.”
“There is some loss of revenue here, but … anything which will help alleviate the broader pressure should help the stock,” he wrote in a research report Monday.
Mr. Gal said he suspects Mylan will continue to receive some heat for its price increases.
In addition, he said, “There will be heightened pressure on [the Food and Drug Administration] to bring competition to market.”
Evercore ISI analyst Umer Raffat called Mylan’s announcement on Monday “a bold move.” But he said questions remained about how the generic program would work, such as whether it would be covered by insurance or whether Mylan would limit the supply.
Mylan’s shares added 19 cents Monday to close at $43.22.
Patricia Sabatini: PSabatini@post-gazette.com; 412-263-3066.





Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.